|
|
|
42
|
4291AP
|
VANCOMYCIN 500MG INJ (FSB)
|
VANCOMYCIN
|
VANCOMYCIN
|
500MG VIAL
|
BQ
|
3.34
|
3.34
|
VIAL
|
56
|
|
FSB
|
FLAGSHIP BIOTECH
|
STO
|
BRYDEN STOKES LTD
|
|
081228
|
ANTIBACTERIALS, MISCELLANEOUS
|
2026-04-01
|
2028-03-31
|
|
IV
|
0
|
ANTIBACTERIALS, MISCELLANEOUS
|
2026-03-05
|
|
|
|
40
|
4291Q
|
VANCOMYCIN 500MG INJ (GLN/AHI)
|
VANCOMYCIN
|
VANCOMYCIN
|
500MG VIAL
|
BQ
|
5.27
|
5.27
|
INJECTION
|
0
|
VIAL
|
GLN
|
GLAND
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
08122816
|
GLYCOPEPTIDES
|
2022-04-01
|
2022-09-30
|
|
IV
|
0
|
ANTI-INFECTIVE AGENTS
|
2022-03-29
|
|
|
|
40
|
4291V
|
VANCOMYCIN 500MG INJ (FSB/ATB)
|
VANCOMYCIN
|
VANCOMYCIN
|
500MG VIAL
|
BQ
|
4.08
|
4.08
|
INJECTION
|
0
|
VIAL
|
FSB
|
FLAGSHIP BIOTECH
|
ATB
|
ANSA TRADING BARBADOS LTD
|
|
08122816
|
GLYCOPEPTIDES
|
2022-04-01
|
2024-03-31
|
|
IV
|
6
|
ANTI-INFECTIVE AGENTS
|
|
|
|
|
41
|
4291V
|
VANCOMYCIN 500MG INJ (FSB) (BQ)
|
VANCOMYCIN
|
VANCOMYCIN
|
500MG VIAL
|
BQ
|
4.13
|
4.1319
|
VIAL
|
56
|
VIAL
|
FSB
|
FLAGSHIP BIOTECH
|
ATB
|
ANSA TRADING BARBADOS LTD
|
|
08122816
|
GLYCOPEPTIDES
|
2024-04-01
|
2026-03-31
|
|
IV
|
0
|
GLYCOPEPTIDES
|
|
|
|
|
40
|
4291W
|
VAREDET 500MG INJ (ABB/PHA) VANCOMYCIN
|
VANCOMYCIN
|
VAREDET
|
10ML VIAL
|
C
|
7.99
|
7.99
|
INJECTION
|
0
|
VIAL
|
ABB
|
ABBOTT
|
PHA
|
PHARMACY SALES CARIBBEAN
|
|
08122816
|
GLYCOPEPTIDES
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
ANTI-INFECTIVE AGENTS
|
|
|
|
|
40
|
4291W
|
VAREDET 500MG INJ (ABB/PHA) VANCOMYCIN (C)
|
VANCOMYCIN
|
VAREDET
|
10ML VIAL
|
C
|
7.99
|
7.99
|
INJECTION
|
|
|
ABB
|
ABBOTT
|
PHA
|
PHARMACY SALES CARIBBEAN
|
|
8122816
|
GLYCOPEPTIDES
|
2022-04-01
|
2023-03-31
|
Delete from contract
|
IV
|
0
|
GLYCOPEPTIDES
|
2023-03-02
|
|
|
|
40
|
42931
|
VANCOMYCIN 1G INJ (KWA/ATB)
|
VANCOMYCIN
|
VANCOMYCIN
|
1G VIAL
|
BQ
|
20.39
|
20.39
|
INJECTION
|
0
|
VIAL
|
KWA
|
KWALITY PHARMACEUTICALS
|
ATB
|
ANSA TRADING BARBADOS LTD
|
|
08122816
|
GLYCOPEPTIDES
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
ANTI-INFECTIVE AGENTS
|
2022-03-30
|
|
|
|
41
|
42931
|
VANCOMYCIN 1G INJ (KWA) (BQ)
|
VANCOMYCIN
|
VANCOMYCIN
|
1G VIAL
|
BQ
|
6.9
|
6.9045
|
VIAL
|
28
|
VIAL
|
KWA
|
KWALITY PHARMACEUTICALS
|
ATB
|
ANSA TRADING BARBADOS LTD
|
|
08122816
|
GLYCOPEPTIDES
|
2024-04-01
|
2025-01-28
|
|
IV
|
0
|
GLYCOPEPTIDES
|
|
|
|
|
41
|
42931
|
VANCOMYCIN 1G INJ (KWA) (BQ)
|
VANCOMYCIN
|
VANCOMYCIN
|
1G VIAL
|
BQ
|
10.85
|
10.85
|
VIAL
|
28
|
VIAL
|
KWA
|
KWALITY PHARMACEUTICALS
|
ATB
|
ANSA TRADING BARBADOS LTD
|
|
08122816
|
GLYCOPEPTIDES
|
2024-05-25
|
2026-03-31
|
|
IV
|
0
|
GLYCOPEPTIDES
|
2024-05-24
|
|
|
|
40
|
42934
|
VANCOMYCIN 1G INJ (MON/PHA)
|
VANCOMYCIN
|
VANCOMYCIN
|
1G VIAL
|
BQ
|
10.41
|
10.41
|
INJECTION
|
0
|
VIAL
|
MON
|
MONTAGE PHARMACEUTICALS
|
PHA
|
PHARMACY SALES CARIBBEAN
|
|
08122816
|
GLYCOPEPTIDES
|
2022-04-01
|
2024-03-31
|
|
IV
|
6
|
ANTI-INFECTIVE AGENTS
|
|
|
|
|
40
|
42938
|
VANCOQURE 1G INJ (FSB/ATB) VANCOMYCIN
|
VANCOMYCIN
|
VANCOQURE
|
10ML
|
BQ
|
10.85
|
10.85
|
INJECTION
|
0
|
VIAL
|
FSB
|
FLAGSHIP BIOTECH
|
ATB
|
ANSA TRADING BARBADOS LTD
|
|
08122816
|
GLYCOPEPTIDES
|
2022-04-01
|
2024-03-31
|
|
IV
|
6
|
ANTI-INFECTIVE AGENTS
|
|
|
|
|
42
|
4293H
|
VANCOMAX 1G INJ (JLP) VANCOMYCIN
|
VANCOMYCIN
|
VANCOMAX
|
8X1G
|
BQ
|
41.45
|
5.18
|
VIAL
|
28
|
VIAL
|
JLP
|
JOHN LEE PHARMACEUTICALS
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
08122816
|
GLYCOPEPTIDES
|
2026-04-01
|
2028-03-31
|
|
IV
|
0
|
GLYCOPEPTIDES
|
|
|
|
|
42
|
4293J
|
VANCOQURE 1G INJ (FSB) VANCOMYCIN
|
VANCOMYCIN
|
VANCOQURE
|
10ML
|
BQ
|
5.03
|
5.03
|
VIAL
|
28
|
|
FSB
|
FLAGSHIP BIOTECH
|
STO
|
BRYDEN STOKES LTD
|
|
08122816
|
GLYCOPEPTIDES
|
2026-04-01
|
2028-03-31
|
|
IV
|
0
|
GLYCOPEPTIDES
|
2026-03-09
|
|
|
|
41
|
43016
|
PMS-PYRAZINAMIDE 500MG TAB (PMS)
|
PYRAZINAMIDE
|
PMS-PYRAZINAMIDE
|
100'S
|
A
|
42.41
|
0.4241
|
TAB
|
120
|
BOTT
|
PMS
|
PHARMASCIENCE
|
COL
|
COLLINS LTD
|
|
081604
|
ANTITUBERCULOSIS AGENTS
|
2024-04-01
|
2026-03-31
|
|
ORAL
|
6
|
ANTITUBERCULOSIS AGENTS
|
|
|
|
|
42
|
43016
|
PMS-PYRAZINAMIDE 500MG TAB (PMS)
|
PYRAZINAMIDE
|
PMS-PYRAZINAMIDE
|
100'S
|
A
|
39.42
|
0.39
|
TAB
|
120
|
BOTT
|
PMS
|
PHARMASCIENCE
|
COL
|
AVENTA BARBADOS
|
|
081604
|
ANTITUBERCULOSIS AGENTS
|
2026-04-01
|
2028-03-31
|
|
ORAL
|
6
|
ANTITUBERCULOSIS AGENTS
|
|
|
|
|
40
|
4301K
|
PYRAZINAMIDE 500MG TAB (CAM/AHI)
|
PYRAZINAMIDE
|
PYRAZINAMIDE
|
30'S
|
A
|
29.90
|
1.00
|
TABLET
|
120
|
TAB
|
CAM
|
MORNINGSIDE PHARMACEUTICALS
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
081604
|
ANTITUBERCULOSIS AGENTS
|
2022-04-01
|
2024-03-31
|
|
Oral
|
6
|
ANTI-INFECTIVE AGENTS
|
|
|
|
|
40
|
43314
|
GLIVEC 100MG CAP (NVS/COL) IMATINIB
|
IMATINIB
|
GLIVEC
|
60'S
|
C
|
2,478.40
|
41.31
|
CAPSULE
|
0
|
CAP
|
NVS
|
NOVARTIS CARIBE SA
|
COL
|
COLLINS LTD
|
|
1000
|
ANTINEOPLASTICS
|
2022-04-01
|
2024-03-31
|
|
Oral
|
0
|
ANTINEOPLASTICS
|
|
|
|
|
41
|
43314
|
GLIVEC 100MG CAP (NVS) IMATINIB (BQ)
|
IMATINIB
|
GLIVEC
|
60'S
|
BQ
|
2478.4
|
41.3067
|
CAP
|
120
|
BOX
|
NVS
|
NOVARTIS CARIBE SA
|
COL
|
COLLINS LTD
|
|
1000
|
ANTINEOPLASTICS
|
2024-04-01
|
2026-03-31
|
|
ORAL
|
6
|
ANTINEOPLASTICS
|
|
|
|
|
42
|
43314
|
GLIVEC 100MG CAP (NVS) IMATINIB
|
IMATINIB
|
GLIVEC
|
60'S
|
BQ
|
2,478.40
|
41.31
|
CAP
|
120
|
BLIS
|
NVS
|
NOVARTIS CARIBE SA
|
COL
|
AVENTA BARBADOS
|
|
1000
|
ANTINEOPLASTICS
|
2026-04-01
|
2028-03-31
|
|
ORAL
|
0
|
ANTINEOPLASTICS
|
|
|
|
|
40
|
4331AA
|
APO-IMATINIB 100MG TAB (APO/COL)
|
IMATINIB
|
APO-IMATINIB
|
30'S
|
BQ
|
33.84
|
1.13
|
TABLET
|
0
|
TAB
|
APO
|
APOTEX INC.
|
COL
|
COLLINS LTD
|
|
1000
|
ANTINEOPLASTICS
|
2022-04-01
|
2024-03-31
|
|
Oral
|
6
|
ANTINEOPLASTICS
|
|
